Harvard researchers leverage spatial glycobiology for cancer research
Hear how the Program of Glyco-Immunology and Oncology (PGIO) is deciphering cancer’s ‘glyco code’ to pave the way for more precise diagnostics and next generation immunotherapies.
Hear how the Program of Glyco-Immunology and Oncology (PGIO) is deciphering cancer’s ‘glyco code’ to pave the way for more precise diagnostics and next generation immunotherapies.
Learn how Inotiv’s proteomics services are helping researchers gain deeper insights into drug target systems, to better select disease models, and quantify pathology data
Reimagining clinical microbiology with key technologies and long-acting therapies
Learn how Blue/Green LED technology is revolutionizing gel imaging in labs producing chocolate alternatives
See how Bio-Rad’s Vericheck ddPCR Kit offers accuracy and ease to ensure AAV vector quality and safety for improved gene therapy outcomes
Watch this on-demand webinar series to discover innovative liquid chromatography solutions designed to provide ultimate performance, particularly for metal-sensitive analytes
Dr. Priya Chockalingam discusses the complexities of cell and gene therapies and how single-cell multimodal analysis can efficiently characterize gene-edited products
Stanford Cancer Center South Bay streamlines chemistry test delivery with CLSI AUTO15, boosting lab efficiency and patient care
Discover how prioritizing reproducibility and method validation can empower researchers to unlock the full potential of metabolomics in advancing biomarker discovery and drug development
Brilliance Candida 2 Agar and Spectra Candida Agar support earlier detection, faster outbreak response and more informed treatment decisions in healthcare settings*
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery
Research grade recombinant protein expands toolkit of available CRISPR nucleases and increases efficiency of homology-directed repair (HDR) to enable more precise genome modifications
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital PCR technology